General Mills Q1 sales, profit beat estimates; reaffirms 2027 outlook
General Mills Q1 sales, profit beat estimates; reaffirms 2027 outlook
Overview
U.S. packaged foods maker's fiscal Q1 sales declined 3%, but beat analyst expectations
Adjusted EPS for fiscal Q1 beat analyst expectations, despite falling 13% in constant currency
Company reaffirmed full-year fiscal 2027 outlook
Outlook
General Mills reaffirms fiscal 2027 organic net sales outlook of down 1.5% to up 0.5%
Company expects fiscal 2027 adjusted operating profit down 13% to down 8% in constant currency
General Mills sees fiscal 2027 adjusted diluted EPS between $3.00 and $3.20
Result Drivers
DIVESTITURE IMPACT - Co said U.S. yogurt divestiture drove reported net sales decline
HIGHER INPUT COSTS - Co attributed declines in adjusted operating profit and segment profits to higher input costs
LOWER VOLUME - Co said lower volume contributed to profit declines in North America Retail and Pet segments
Company press release: ID:nBwbGd9Kja
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Sales | Beat | $4.39 bln | $4.33 bln (14 Analysts) |
Q1 Adjusted EPS | Beat | $0.75 | $0.72 (15 Analysts) |
Q1 EPS |
| $0.74 |
|
Q1 Gross Margin |
| 33.90% |
|
Q1 Adjusted Gross Margin |
| 33.30% |
|
Q1 Operating profit |
| $633.60 mln |
|
Reuters Recommended Reads
Sept 23 - JD Sports Fashion HY revenue falls on weaker footwear demand
Sept 22 - Kingfisher H1 profit rises, lifts annual adjusted PBT forecast
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on General Mills
See all newsKraft Heinz backs protein, fiber trends as innovation drive gains steam
Brief: General Mills Announces Cash Tender Offers For Its Senior Notes
McCormick's price hikes spice up quarterly results despite sluggish demand (updated)
McCormick beats quarterly sales estimates
U.S. STOCKS ON THE MOVE-Pyxis Oncology, MongoDB, United Therapeutics